Synvect, a San Diego, CA-based biotechnology startup growing vector management options, raised $3M in Seed funding.
Backers included Invoice & Melinda Gates Basis, Antler, NuFund, and Redbud.
The corporate intends to make use of the funds to speed up the event and deployment of its CRISPR-based expertise, providing an eco-friendly resolution to suppress disease-carrying mosquito populations.
Led by CEO Dr. Nikolay Kandul, Synvect is a biotechnology startup dedicated to eliminating vector-borne ailments by scalable, precision-driven mosquito suppression expertise. Constructing on 15 years of analysis and $20M in prior funding, Synvect makes use of CRISPR to supply sterile male mosquitoes, which, when launched, mate with wild females—who solely mate as soon as—stopping replica.
Synvect has acquired U.S. Environmental Safety Company (EPA) approval for its first product, SEPARATOR, paving the way in which for industrial deployment. The corporate is launching pilot applications with authorities and mosquito management companies in Florida, Texas, California, and different high-risk areas.
FinSMEs
11/03/2025
